Clinical Trials Logo

Advanced Cancers clinical trials

View clinical trials related to Advanced Cancers.

Filter by:

NCT ID: NCT06413953 Not yet recruiting - Advanced Cancers Clinical Trials

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Start date: May 2024
Phase: Phase 1
Study type: Interventional

TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).

NCT ID: NCT06001749 Not yet recruiting - Advanced Cancer Clinical Trials

Psilocybin in Cancer Pain Study

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)

NCT ID: NCT05380882 Recruiting - Advanced Cancers Clinical Trials

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

Start date: May 2022
Phase: Phase 1
Study type: Interventional

TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.

NCT ID: NCT05333276 Active, not recruiting - Advanced Cancers Clinical Trials

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Start date: July 29, 2022
Phase: Phase 1
Study type: Interventional

TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody.

NCT ID: NCT03726333 Terminated - Advanced Cancers Clinical Trials

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Start date: January 14, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

NCT ID: NCT03375983 Recruiting - Advanced Cancers Clinical Trials

Plasmodium Immunotherapy for Advanced Cancers

Start date: November 23, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

NCT ID: NCT02873975 Completed - Advanced Cancers Clinical Trials

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Start date: October 12, 2016
Phase: Phase 2
Study type: Interventional

This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.

NCT ID: NCT02801045 Completed - Clinical trials for Psychological Stress

Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient

Start date: October 20, 2016
Phase: N/A
Study type: Interventional

This study evaluates from the patient's perspective which elements of the own artistic creative process are the source of a beneficial change for him/her and how those elements influence in their end of life experience.

NCT ID: NCT02668770 Active, not recruiting - Melanoma Clinical Trials

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Start date: May 11, 2016
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of MGN1703 that can be given in combination with ipilimumab to patients with advanced tumors. The safety of this drug combination will also be studied. This is an investigational study. MGN1703 is not FDA approved or commercially available. It is currently being used for research purposes only. Ipilimumab is FDA approved and commercially available for the treatment of unresectable (cannot be removed with surgery) or metastatic (has spread) melanoma. Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT02623959 Terminated - Advanced Cancers Clinical Trials

Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis

Start date: April 27, 2016
Phase: Phase 4
Study type: Interventional

The goal of this clinical research study is to compare indwelling pleural catheters (IPC) in combination with saline (the current standard of care) versus IPC in combination with doxycycline as treatment for pleural effusions.